Tumor relevant protein functional interactions identified using bipartite graph analyses

Divya Lakshmi Venkatraman1,2, Deepshika Pulimamidi1,2, Harsh G. Shukla1 & Shubhada R. Hegde1,*

An increased surge of -omics data for the diseases such as cancer allows for deriving insights into the affiliated protein interactions. We used bipartite network principles to build protein functional associations of the differentially regulated genes in 18 cancer types. This approach allowed us to combine expression data to functional associations in many cancers simultaneously. Further, graph centrality measures suggested the importance of upregulated genes such as BIRC5, UBE2C, BUB1B, KIF20A and PTH1R in cancer. Pathway analysis of the high centrality network nodes suggested the importance of the upregulation of cell cycle and replication associated proteins in cancer. Some of the downregulated high centrality proteins include actins, myosins and ATPase subunits. Among the transcription factors, mini-chromosome maintenance proteins (MCMs) and E2F family proteins appeared prominently in regulating many differentially regulated genes. The projected unipartite networks of the up and downregulated genes were comprised of 37,411 and 41,756 interactions, respectively. The conclusions obtained by collating these interactions revealed pan-cancer as well as subtype specific protein complexes and clusters. Therefore, we demonstrate that incorporating expression data from multiple cancers into bipartite graphs validates existing cancer associated mechanisms as well as directs to novel interactions and pathways.

Cancer is proving to be one of the deadliest diseases, with 18 million new cases and 9.6 million deaths in 20181. This invites attention for research, diagnosis and treatment of cancer. Cure for cancer is elusive due to the heterogeneity and complexity of its manifestation1. Decades of research on cancer has accumulated information regarding histopathology, gene expression, signaling events and protein interactions (reviewed in Ref.3,4). For long, cancer studies were largely focused on the molecular level. With the emergence of systems biological approaches, information such as gene expression and pathway functioning are integrated to generate holistic perspective for the diseases such as cancer5.

One of the efficient ways to understand the difference between cancer cells and their normal counterparts is to study their differential gene expression signatures. The large-scale expression data for cancer and normal samples derived from the RNA-seq experiments available in multiple databases facilitate such system-wide analyses. Apart from studying individual cancer types, data from multiple cancers could be combined to understand common principles governing disease establishment and their inter-connectedness. This is useful in distinguishing pathways and proteins which are unique to a given cancer from the ones that are shared by multiple cancers. Pan-Cancer analysis project is one such attempt by TCGA (The Cancer Genome Atlas) to characterize cancers according to their molecular and genetic profiles6. Earlier, DNA microarray data spanning multiple cancers was analysed to obtain functional modules of genes showing expression or repression for a given cancer7. Also, microarray-based gene expression data from multiple cancers were considered to identify functional pathways that are dysregulated across various cancer types8,9. Along similar lines, RNA-seq data based study reported differential gene expression signatures across 33 human cancer types as well as between highly and lowly-advanced cancers10. The differential gene expression information was also mapped onto known protein complexes to establish connections between cancers and their corresponding enriched protein complexes11. In another study, systematic cataloging of somatic mutations was performed to obtain mutational signatures in many different cancers12. Likewise, in a pan-cancer mode, somatic copy number variations were analysed to identify their common patterns of occurrence in cancer13. Over the years, such studies proved widely informative in establishing relatedness between different cancers. Besides these, it is useful to view the differentially regulated genes as functionally interacting proteins based on their expression pattern in multiple cancers.

1Institute of Bioinformatics and Applied Biotechnology (IBAB), Bengaluru 560 100, India. 2These authors contributed equally: Divya Lakshmi Venkatraman and Deepshika Pulimamidi. *email: shubhada@ibab.ac.in
signaling networks and phosphorylation networks. Bipartite networks, on the other hand, represent interactions between two sets of nodes where the connections run only across the sets. Many relationships in the real-world systems—including centrality, clusters and motifs of the derived networks revealed important proteins and pathways associated with cancer. Our study, therefore, emphasizes on how the graph theoretical method, namely bipartite network analysis, can be effectively used in cancer systems biology to integrate the emerging large-scale data.

Results
Identifying differentially expressed genes across multiple cancer types. We used RNA-seq data corresponding to 18 cancer types along with their control samples to obtain differential gene expression. There were 10,107 and 9167 genes identified as up and downregulated in one or more cancers, respectively, with an overlap of 5333 genes (Table 1, Supplementary Table S1). Of these, many genes were differentially expressed in only one or a few cancers while some were differentially expressed across many cancer types (Fig. 1). For example, Parathyroid Hormone 1 Receptor (PTH1R) and collagen-binding Dermatopontin (DPT) were downregulated in all the 18 cancers. Previously, decreased DPT expression was seen in uterine leiomyomas. Also, expression of the PTH1R was significantly reduced in hepatocellular carcinoma compared to normal liver tissues. In line with our observations, the downregulation of PTH1R and DPT could be important for most of the cancers.

| Cancer type                                   | Normal samples | Tumor samples | Genes upregulated | Genes downregulated |
|----------------------------------------------|----------------|---------------|--------------------|---------------------|
| Bladder urothelial carcinoma (BLCA)          | 28             | 362           | 1724               | 1390                |
| Breast invasive carcinoma (BRCA)             | 322            | 298           | 2409               | 2305                |
| Cervical and endocervical cancers (CESC)     | 13             | 259           | 2529               | 2030                |
| Colon adenocarcinoma (COAD)                  | 380            | 285           | 2292               | 3260                |
| Esophageal carcinoma (ESCA)                  | 670            | 183           | 2885               | 2359                |
| Head and Neck squamous cell carcinoma (HNSC) | 97             | 460           | 1593               | 2605                |
| Kidney renal clear cell carcinoma (KIRC)     | 104            | 475           | 1780               | 1389                |
| Liver hepatocellular carcinoma (LIHC)        | 163            | 295           | 1581               | 912                 |
| Lung adenocarcinoma (LUAD)                   | 372            | 503           | 2502               | 2040                |
| Prostate adenocarcinoma (PRAD)               | 154            | 426           | 963                | 2220                |
| Stomach adenocarcinoma (STAD)                | 225            | 380           | 1984               | 1943                |
| Thyroid carcinoma (THCA)                     | 371            | 441           | 1372               | 2135                |
| Uterine Corpus Endometrial Carcinoma (UCEC)  | 105            | 141           | 3411               | 2409                |
| Cholangiocarcinoma (CHOL)                    | 9              | 31            | 2680               | 1566                |
| Kidney Chromophobe (KICH)                    | 25             | 60            | 1388               | 1909                |
| Kidney renal papillary cell carcinoma (KIRP) | 29             | 236           | 1353               | 1162                |
| Lung squamous cell carcinoma (LUSC)          | 51             | 489           | 3338               | 2657                |
| Rectum adenocarcinoma (READ)                 | 10             | 87            | 2667               | 3807                |

Table 1. List of cancer types included in the study along with the number of normal and tumor samples and their differentially regulated genes.
progression. Elevated expression of UBE2C also correlates with poor survival and increased risk for relapse\(^3\). A member of the serine/threonine kinase protein family NEK2 also shows overexpression in multiple cancer types which is indicative of relapse and poor survival\(^3\). Some of the other upregulated genes include centromere proteins (CENPA, CENPF and CENPM), kinesin family members (KIF20A and KIF4A), DNA replication factor CDT1, Holliday junction recognition protein HJURP, and G2 and S phase-expressed protein GTSE1. Pan-cancer expression analysis, therefore, suggests the importance of these differentially expressed genes in cancer. 

High centrality nodes in the cancer associated bipartite networks. In order to connect the cancer types and their differentially regulated genes, we built two cancer-gene association networks representing the up and the downregulated genes. Differentially regulated genes were modeled as bipartite graphs \(BG = (C, G, E)\), where \(C\) is the set of nodes representing a cancer type, \(G\) is the set of nodes representing differentially expressed genes and \(E\) is the set of edges in the graph.

Further, we tested whether the distribution of the node redundancy coefficients in the real networks are different than the distribution in random networks with similar degrees. For this, 10 random bipartite networks with degree distributions similar to the real network were created using a configuration model, thereby ensuring that the scale free property of the generated random networks is preserved. These random networks and the two real networks representing up and downregulated genes in cancer were compared using two-sample Kolmogorov Smirnov test for the distributions of the node redundancy coefficients ("Methods"). For the upregulated bipartite network, the average D-statistic of the node redundancy coefficient was 0.833 (P-value < 1.5E−06). Similarly, for the downregulated bipartite network, the average D-statistic of the node redundancy coefficient was 0.788 (P-value < 1.3E−05). Significantly high D-statistic for node redundancy in each of these comparisons suggested that the generated bipartite networks for the up and downregulated genes in cancer were indeed different from the random networks, thus implying their biological significance. For these bipartite graphs, topological indexes such as centralities were calculated which score the nodes by estimating their importance in the network\(^3\). Degree centrality in a bipartite measures the number of connections a node makes in the opposite node set. Therefore, genes which are up or downregulated in multiple cancers are evaluated as important by the degree centrality measure. Closeness centrality evaluates how rapidly a given node can communicate with the other nodes in a network through short paths. In a bipartite graph, a node can have a minimum distance of 1 to all nodes of the other set and a minimum distance of 2 from all nodes of its own set. Likewise, high betweenness centrality in a bipartite network implicates nodes that mediate communication between other pairs of nodes via multiple shortest paths crossing through them. Therefore, these centrality measures provide diverse aspects of node importance in the bipartite network. We aggregated the top 5% nodes of the betweenness, closeness and degree centrality measures, which yielded 616 and 619 genes for the downregulated and upregulated networks, respectively, without any overlap (Supplementary Table S2). We observe that 66% (407 out of 619) and 51% (313 out of 616) of the top 5% aggregates are evaluated as important by all the three centrality measures for the up and downregulated networks, respectively. A close inspection of these individual centrality measures revealed that while top 5% of degree centrality results were nodes with a minimum degree of 11 for the upregulated and 12 for the downregulated network, top 5% of the closeness and the betweenness centrality measures shortlisted some of the nodes which were differentially regulated even in 8 cancer types (Supplementary Fig. S1). Hence, we considered these genes as significant for further analyses.

Figure 1. Bar plot representing the frequency of the differentially expressed genes against number of cancers. There are many genes which appear as differentially regulated in one or a few cancer types. However, comparatively smaller set of genes are differentially regulated in many cancer types.
Pathway enrichment of the high centrality genes in both up and downregulated bipartite networks was performed using Enrichr (KEGG pathway enrichment with adjusted P-value < 0.05)\(^\text{27}\). Cell cycle, Fanconi anemia pathway, DNA replication, homologous recombination and P53 signaling are some of the prominent pathways represented by the upregulated high centrality nodes (Fig. 2a). On the other hand, Dilated cardiomyopathy, Vascular smooth muscle contraction, Hypertrophic cardiomyopathy, Adrenergic signaling in cardiomyocytes and Arrhythmogenic right ventricular cardiomyopathy pathways were enriched for the downregulated high centrality nodes (Fig. 2b). The downregulated proteins from these pathways included actins (ACTC1, ACTG2), myosins (MYH11, MYH7, MYLK, MYL3, MYL9), protein phosphatase 1 regulatory subunits (PPP1R1A, PPP1R14A, PPP1R1A), microRNA protein coding genes (CTNNA3, DMD, MYH7, PDE2A), complement proteins (C1R, C6, C7, CFD) and ATPases (ATP1A2, ATP1B2). Apart from their primary functions such as muscle contraction, motility process, transport and metabolism, these genes also participate in various other cellular processes. For example, actins are involved in cell division, migration and signaling, myosins are associated with cell migration and adhesion, and protein phosphatase 1 regulatory subunits are implicated in cell cycle progression, protein synthesis, transcription and neuronal signaling\(^\text{33–35}\). Importantly, few of these proteins, namely, ATP1B2, CTNNA3 and MYLK were reported to be downregulated biomarkers in glioma, hepatocellular and breast carcinoma, respectively\(^\text{36–38}\). Therefore, it appears important to investigate the functional implications associated with the downregulation of these proteins in cancers.

The nodes which we identified as central in cancer associated bipartite graphs were either up or downregulated in multiple cancers. Such a behavior is governed by the transcription factors which act as activators and/or repressors of gene expression. We tested the transcription factor enrichment for the 1235 differentially regulated high centrality genes. For further analysis, we considered top 25% enriched transcription factors with adjusted P-value < 0.05 which regulate 10 or more high centrality genes. The complete list of regulatory interactions is given in Supplementary Table S3. We observe that the mini-chromosome maintenance proteins (MCMs) MCM2, MCM3, MCM6 and MCM7, which were upregulated in most of the cancers, also regulate the expression of a significant number of high centrality genes in the network. In addition, many high centrality differentially regulated genes in cancer were regulated by the E2F family genes, of which E2F4 alone regulates about 344 genes. E2F1, E2F2 and E2F7 proteins, which were upregulated in most of the cancer types and appear as high centrality nodes in the bipartite graphs, regulate around 224, 93 and 74 high centrality genes, respectively (Supplementary Table S3). As E2F family transcription factors participate in cell cycle control, the overexpression of E2F family genes and their subsequent gene regulatory activities might have significant implications on cancer cell proliferation. We also observed that transcription factors E2F4 and ETS1 regulate 41 and 38 of the 43 genes which were upregulated in all the cancers, respectively (Supplementary Tables S1 and S3). Some of the other enriched transcription factors include MYB, BRCA1, STAT1 and ETV4 which are upregulated in majority of the cancer types. On the other hand, Retinoid X receptor RXRG which is a regulator of 15 high centrality differentially regulated genes is downregulated in 12 cancer types. Earlier in an ovarian adenocarcinoma progression model, activation of RXRG by retinoid treatment sensitized the cells to apoptosis\(^\text{39}\). Further analysis of the genes which are differentially expressed in most of the cancers and also regulate many high centrality nodes in the network could provide more insights on the common principles governing tumor development.

**Weighted one-mode projection of the cancer associated bipartite networks.** Depending on the nature of expression across different cancer types considered, we derived functional association between differentially regulated genes in the original bipartite networks. The one-mode projection of a bipartite graph results in two sets of unipartite graphs in which two nodes of G (or C) are connected if they have at least one edge in common in the original bipartite graph (Supplementary Fig. S2). To obtain cancer specific protein functional interactions, we projected the bipartite graphs representing up and downregulated genes onto their respective unipartite graphs. While projecting, each edge in these graphs were weighted using a Jaccard index to account

---

**Figure 2.** Bar plots representing the enriched pathways of the top 5% high centrality nodes (Adjusted P-value versus Combined score). Combined score represents the product of logarithmic P-value computed using Fisher exact test and z-score. These scores for each pathway are obtained from Enrichr (gene enrichment analysis web-based tool). (a) Upregulated, (b) downregulated.
for the similarity in association (“Methods”). The distribution of the number of components and the size of the largest component at various weight-cutoff are provided in Supplementary Fig. S3. In order to eliminate insignificant edges, we used 0.9 as the edge weight cutoff and analyzed the resulting protein functional interaction networks. These comprised of 37,411 edges among 4544 nodes and 41,756 edges among 4584 nodes for the up and the downregulated genes, respectively (Supplementary Table S4). While many of these interacting proteins are differentially regulated in majority of the cancer types, some of them seem to be specific for the known cancer subtypes.

There was an overlap of 479 interactions (P-value < 2.50E−162) among 363 proteins between the upregulated projected network and the curated protein–protein interaction network (Supplementary Table S5a). These include extensive interactions among proteins AURKB, BUB1, BUB1B, BIRC5, CCNB2, CDK1, CDCA5, CDCA8, CENPE, CENPM, CENPI, CENPH, CENPA, ERCC6L, NDC80, NUF2, SKA1, SPC24, and SPC25 (Supplementary Table S5a). Also, there were 67 known interactions between 112 (P-value < 7.43E−03) proteins in the downregulated projected network. While some of these proteins such as SNRNP70 and SRSF5 are the components of the spliceosome complex, the others, namely, SORBS1, TPM2 and MYH11 were reported to have a role in tumor metastasis and development (Supplementary Table S5a)41–43. These up and downregulated proteins were differentially expressed in more than 8 cancer types studied. Additionally, the projected upregulated network had 77 known regulatory interactions of the transcription factors including E2F1, E2F7, MCM2 and MCM4 (Supplementary Table S5b). The downregulated projected network had 62 known regulatory interactions, of which transcription factors TAL1, ZEB1 and MEIS1 regulate the genes which were differentially regulated in more than half of the cancers studied (Supplementary Table S5b). The upregulated transcription factors E2F1, E2F7, MCM2 and MCM4, as previously mentioned, belong to the group of 25% high centrality nodes and therefore their activities might be important for cancer development.

The largest component of the up and downregulated network consisted of 6498 edges between 564 nodes and 9984 edges between 850 nodes, respectively. We observed that the genes which were part of these largest components were differentially regulated in 9 or more cancer types. These were compared with 4274 protein complexes derived from CORUM database to verify if we captured any known protein complexes. There were 14 protein complexes which showed overlapping interactions with the largest components of the projected networks. Some of the complexes found in the upregulated projected networks are shown in Fig. 3. NDC80 kinetochore complex, which plays a key role in chromosome alignment and segregation during mitosis, comprises of 4 components namely, NDC80, NUF2, SPC24 and SPC25. Out of the 6 possible interactions among these components, we captured 4 interactions in our network (Fig. 3a). NDC80 Kinetochore complex was previously reported to be involved in various types of cancers, including prostate and breast cancer44–46. In addition to the interactions

**Figure 3.** Interactions of the projected upregulated protein complexes. Rectangle shaped nodes are part of the upregulated projected network and the ellipse shaped nodes are differentially regulated components of the complex. Hexagons—other components of the complex. The red colored edges are the captured interactions between complex components in the projected network. (Blue nodes—upregulated, green nodes—downregulated and grey nodes – not differentially regulated) (a) NDC80 kinetochore complex, (b) cell cycle kinase complex, (c) chromosomal passenger complex (CPC), (d) mini-chromosome maintenance (MCM) protein complex, (e) Centromere (CEN) complex and (f) ECT2–KIF23–RACGAP1 complex.
between cell cycle kinase complex proteins CCNB1, CDK1 and CCNF (Fig. 3b), interactions of chromosomal passenger complex components AURKB, BIRC5 and CDC45 were also recorded (Fig. 3c). Chromosomal passenger complex regulates cell division and has been implicated in breast cancer44. The MCM complex which plays a major role in cellular development and cell cycle consists of 6 components, MCM2–MCM7, of which MCM2, MCM4 and MCM6 were found to interact in the projected upregulated network (Fig. 3d). Also, interactions between the proteins CENPA, CENPM, CENPK, CENPH and HJURP were identified which belong to centromere complex that regulates the kinetochore and spindle assembly (Fig. 3e). The network consisted of interactions among ECT2, KIF23 and RACGAP1 which belong to a complex associated with cytoskeleton function (Fig. 3f). The upregulated network also showed an interaction between the transcription factor RUVBL1 and the gene ACTL6A. RUVBL1 and ACTL6A are the components of various protein complexes such as uA4/Tip60 HAT, p400-associated, c-MYC-ATPase-helicase, TIP49-TIP48-BAF53, INO80 chromatin remodeling, SRCAP-associated chromatin remodeling and TIP60 histone acetylase. The c-MYC-ATPase-helicase complex was found to associate with the complexes TIP49-TIP48-BAF53 and NuA4/Tip60 and reported to be involved in cell transformation and cancer47. Of the many downregulated spliceosome complex proteins in cancer, we captured the interactions between SNRNP70, SR5F5, DDX17 and LUC7L3 in the largest component of the projected downregulated network (Supplementary Fig. S4). We speculate that the downregulation of these proteins might affect the splicing of the genes that are likely to be associated with cell cycle events and signal transduction, and therefore might trigger these cellular mechanisms towards cancer. Importantly, the above-mentioned proteins of the functional complexes were differentially expressed in more than half of the cancer types that we have studied, suggesting their relevance in the context of pan-cancer analyses.

Further, we clustered the largest component of the projected networks to identify groups of genes which closely interact in the network. Their interconnection is associated with their functional relatedness, therefore revealing co-regulated functions associated with tumor and its progression. CytoCluster resulted in 90 and 173 clusters for the largest components of the up and downregulated projected networks, respectively (Supplementary Table S6). Of these, 63 upregulated and 143 downregulated clusters showed significant enrichment for two or more pathways (KEGG, P adjusted < 0.05, Supplementary Table S6). These pathway-level cross-talks could be insightful in suggesting the underlying mechanisms across multiple cancers. One of the upregulated clusters (Cluster-16) comprised of MCM proteins (MCM2, MCM4 and MCM6) along with cell cycle (P-value < 4.71E−22) proteins CCNA1 and CDK1, and DNA replication (P-value < 5.61E−07) proteins such as ORC1and PCNA, thus attributing functions such as cell cycle regulation and arrest, cell proliferation and DNA replication to the cluster (Supplementary Table S6a and Fig. 4a). Also, another upregulated cluster (Cluster-84) constituted genes belonging to Homologous recombination (P-value < 1.36e−05) and Fanconi Anemia pathways (P-value < 1.15E−06), which are known to be associated with DNA repair mechanisms48 (Supplementary Table S6a and Fig. 4a). Genes belonging to this cluster such as EM1 (Essential meiotic endonuclease 1), FANCI (Fanconi Anemia Complementation Group I) and RAD54L (DNA Repair and Recombination Protein RAD54-Like) are associated with functions related to repairing DNA damage, maintaining genomic stability and mitotic and homologous recombination.

Likewise, one of the clusters (Cluster-28) in the largest component of downregulated network were associated with the pathways such as calcium signaling (P-value < 3.27E−03) and sensory transduction (P-value < 2.62E−03) (taste transduction) (Supplementary Table S6b and Fig. 4c). Downstream of sensory transduction involves the activation of G-protein coupled receptors (GPCRs) and voltage gated channels which are essential for proper cellular functioning49,50. Genes belonging to this cluster such as members of calmodulin dependent phosphodiesterase family (PDE1B and PDE1C) regulate the second messengers, which are the key regulators of many physiological processes. Also, GABBR1 (Gamma-aminobutyric acid type B receptor subunit 1) modulates the activity of voltage-dependent calcium channels. Individually these pathways are involved in intracellular signaling49,50, their co-downregulation might be an important aspect to study across cancers.

Another downregulated cluster (Cluster-74) consisted of genes involved in vascular smooth muscle contraction (P-value < 6.48E−06), dilated (P-value < 4.40E−05) and hypertrophic cardiomyopathy pathways (P-value < 4.87E−04), which are primarily involved in muscle contraction (Supplementary Table S6b and Fig. 4d). Members involved in this pathway such as Adenyl cyclase (ADCY4 and ADCY5) and Actin proteins [ACTG2 (Actin Gamma 2, Smooth Muscle) and TPM2 (Tropomyosin 2)] are associated with functions such as GPCR signaling, cell motility and calcium dependent smooth muscle contraction. Therefore, downregulation of these pathways together might be an important factor for cancer. Such interactions of the differentially regulated genes at multiple levels, such as complexes and clusters will be informative in revealing mechanisms that are crucial across multiple cancers.

**Identifying subtype-specific interactions.** While the largest components showed enrichment for all or most of the cancers studied, some of the other network components were differentially regulated in known cancer subtypes (Supplementary Table S4)48. The upregulated component enriched for the cancer subtypes Bladder urothelial carcinoma (BLCA), Head and Neck squamous cell carcinoma (HNSC) and Lung squamous cell carcinoma (LUSC) showed interactions among proteins belonging to MAGE family (Melanoma Antigen gene—functions as drivers of tumorigenesis), namely, MAGEA9 (Melanoma Associated Antigen 9), MAGEB9 (Melanoma Antigen Family A9B), MAGEB6 (Melanoma-Associated Antigen B6) and MAGEC1 (Melanoma-Associated Antigen C1). Since MAGE family members promote the transformation of fibroblasts and increase the growth of cancer cells, their differential expression and interaction might be important for cancer subtypes BLCA, HNSC and LUSC (Supplementary Fig. S5)31. Also, the upregulated interactions that characterize COAD and READ cancer subtypes include interactions between proteins belonging to gene groups Small Nucleolar RNA (snoRNAs) and WD repeat domain containing protein. One such example is the interaction between
NOP56 (Nucleolar Protein 56) and NLE1 (Notchless Homolog 1) (Supplementary Fig. S6a). On the other hand, interactions between Zinc fingers C2H2-type proteins were observed in the downregulated network component which is specific to COAD and READ cancer subtypes (Supplementary Fig. S6b). Similarly, one of the upregulated component specific to Kidney renal clear cell carcinoma (KIRC) and Uterine corpus endometrial carcinoma (UCEC) cancer subtype showed interaction between CHST9 (Carbohydrate Sulfotransferase 9—mediates cell–cell interactions and signal transduction), RGS13 (Regulator of G-protein signaling—implicated in GTPase activator activity) and NOG (Noggins—involved in the development of various body tissues). Also, the interaction between VAW7 (Von Willebrand Factor A Domain Containing 7) and WNT4 (Wnt Family Member 4—implicated in oncogenesis) was observed in the downregulated network component for KIRC and UCEC cancer subtypes. While VAW7 is known to mediate platelet-tumor cell interactions, WNT4 is involved in the development of kidney, genital system, lung and other organs. Impaired kidney development was earlier observed in the gene knockout studies of WNT4. Additionally, downregulation of WNT4 in endometrial cancer cell lines and tumors was previously reported. Collectively, these interaction data provide insights on the functions which represent pan-cancer as well as the cancer subtypes.

Discussion
Cancer manifestation in different tissue types needs to be analyzed in conjunction to obtain their unifying themes. Previously, genome analyses of different cancer types uncovered mutation and copy number variation landscapes. Many such events at the genomic level percolate into gene expression and thereby modulate downstream protein activities. Using publicly available RNA-seq data, we profiled gene expression in various cancer tissues and compared them with the corresponding normal tissues to obtain differentially regulated genes. We observed a significant number of genes that are differentially regulated in multiple cancers. While genes such as PTH1R, DPT, DES, TCF21 and PDE2A are downregulated in all the cancer types we studied (Supplementary Table S1). Using graph theoretical approaches, we revisited pan-cancer analysis to connect differential gene expression across multiple cancer types. This systems-level approach led us to dissect general principles associated with cancer in terms of important cancer driver genes, their functional interactions and pathways, which were not evident from the individual data otherwise.
The graph properties of the bipartite networks that we built using differentially regulated genes were largely different from the random networks, suggesting underlying biological reasons to these networks. High centrality genes in the upregulated network pointed towards pathways such as cell cycle, DNA replication and F53 signaling as prominent for cancer manifestation. On the other hand, proteins from actin, myosin, protein phosphatase 1 regulatory subunits and ATPases gene groups were represented as the downregulated high centrality nodes. Our work reiterated the importance of mini-chromosome maintenance proteins (MCMs) and E2F family transcription factors in regulating the expression of a large number of differentially regulated genes in cancer. The functional interaction network built by projecting the bipartite graphs highlighted the protein–protein associations which could be significant for cancer. We also borrowed information from the other large-scale data, namely, regulatory interactions, protein complexes and known protein–protein interactions to gain functional perspectives on the derived proteins and their interactions. The super-associations of protein interactions such as complexes and clusters revealed proteins from the NDC80 kinetochore complex, MCM complex, centromere complex and spliceosome complex as important interactors mediating cancer progression. Some of the interactions in the projected networks appeared to be cancer subtype specific. While extensive interactions between MAGE family genes such as MAGEA9, MAGE9B, MAGEB6 and MAGEC1 correspond to the cancer subtypes BLCA, HNSC and LUSC, interactions between zinc fingers C2H2-type proteins in the downregulated components characterized COAD and READ cancer subtypes. Together, these approaches exemplify bipartite graph means to connect and study multi-layer information. Apart from these data serving as a useful resource for the cancer-associated protein functional interactions, we believe that a similar method could be potentially applied to study other pan-cancer data such as DNA mutation, differential methylation, copy number variation and small RNA expression.

**Methods**

**Differential gene expression in cancer.** Consolidated RNA-seq data from Genotype Tissue Expression project (GTEx) and The Cancer Genome Atlas (TCGA) databases were obtained from24,55. A summary of the samples and differentially expressed genes with respect to their cancer types (n = 18) are given in Table 1. In this method, RNA-seq raw reads of 18 cancer types along with their control were realigned and quantile normalized for quantifying gene expression. edgeR (Empirical analysis of Digital gene expression in R) v3.24.3, a Bioconductor software package for examining the differential expression of replicated count data was used to identify DEGs with adjusted P-value < 0.05 using Benjamini and Hochberg method and absolute log fold change of ≥ 156. Two bipartite networks representing up and downregulated genes were established using NetworkX v2.2, package in python by connecting cancer types to their differentially regulated genes as shown in the Supplementary Fig. S2. In this graph, C is the set of nodes representing a cancer type, G is the set of nodes representing differentially expressed genes and E is the set of edges in the graph.

**Bipartite network analysis.** NetworkX was used for studying bipartite network properties (https://networkx.github.io/documentation/latest/overview.html). Centrality measures for the bipartite graphs were calculated using definitions given in Ref.35, and derived as below:

I. For the bipartite graph, $BG = (C, G, E)$, the degree centrality for node $c$ (or $g$) is calculated as:

$$D_c = \frac{\text{deg}(c)}{G_n},$$

$$D_g = \frac{\text{deg}(g)}{G_n},$$

where \(\text{deg}(c)\) is degree of node $c$, for $c \in C$, \(\text{deg}(g)\) is degree of node $g$, for $g \in G$, $C_n$ is number of nodes in set $C$, $G_n$ is number of nodes in set $G$.

II. For the bipartite graph, $BG = (C, G, E)$, the closeness centrality of node $c$ (or $g$) is calculated as:

$$\text{Closeness}_c = \frac{G_n + 2(C_n - 1)}{d_c}, \quad \text{for} \ c \in C,$$

$$\text{Closeness}_g = \frac{C_n + 2(G_n - 1)}{d_g}, \quad \text{for} \ g \in G,$$

where $d_c$ and $d_g$ are respectively the sum of geodesic distances from node $c$ and node $g$ to all the other nodes in the graph, $G_n$ is number of nodes in set $G$, $C_n$ is number of nodes in set $C$.

III. For a bipartite graph $BG = (C, G, E)$, the normalized betweenness centrality of node $c$ (or $g$) is calculated as:

$$\text{Bet}(c) = \frac{B(c)}{\frac{1}{2} \left[ G_n^2 (s + 1)^2 + G_n (s + 1)(2t - s - 1) - t(2s - t + 3) \right]},$$

where $B(c)$ is betweenness of node in $c$, \(\text{Bet}(c)\) is normalized betweenness centrality of node $c$. 
\[ s = (C_n - 1) \div G_n, t = (G_n - 1) \mod G_n. \]

\[ Bet(g) = \frac{B(g)}{\frac{1}{2} \left[ C_n^2 (p + 1)^2 + C_n (p + 1) (2r - p - 1) - r(2p - r + 3) \right]}, \]

where \( B(g) \) is betweenness of node in \( g \), \( Bet(g) \) is normalized betweenness centrality of node \( g \).

\[ p = (G_n - 1) \div G_n, r = (G_n - 1) \mod G_n. \]

Union of the top 5% nodes that show high centrality in either of the three measures were taken for further analysis.

Pathway enrichment for the high centrality nodes was analyzed using Enrichr. Gene regulatory network (GRN) was built by combining data from TRRUST, HTRIdb, Human Regulatory Network derived from ENCODE and RegNetwork databases. In total, 226,782 gene regulatory interactions between 1604 transcription factors and 22,485 target genes were obtained. The P-values for the enriched transcription factors were calculated using hypergeometric distribution and adjusted using Benjamini–Hochberg method.

A statistical validation of the bipartite network was performed by comparing node redundancy coefficients between the real networks and 10 random bipartite networks. Random networks were generated using configuration model which creates random graphs from a given degree distribution. The function configuration_model in NetworkX version 2.2 was used to create random bipartite graphs by preserving the degrees of the nodes of each node set in the original network (https://networkx.org/). The node redundancy coefficients between each of the random networks and the gene-cancer bipartite network were compared to test if they are from the same distribution. For this, two-sample Kolmogorov–Smirnov test was performed using scipy.stats package in Python (http://www.scipy.org/) and the average D-statistics of the distributions were reported. The D-statistic of the two sample Kolmogorov–Smirnov test measures the largest vertical distance between two empirical distributions. The D-critical value is 0.019 and 0.020 for the upregulated and the downregulated networks, respectively. The samples are concluded to be drawn from different distributions if the D-statistic is greater than the D-critical value.

**One mode projected network analysis.** The one-mode projection networks for both up and downregulated networks were generated using overlap-weighted projection. The weights in the one-mode projection represent the Jaccard index between neighborhoods of the two nodes in the original bipartite network as given by the equation:

\[ w_{(u,v)} = \frac{|N(u) \cap N(v)|}{|N(u) \cup N(v)|}, \text{where } u, v \in G(\text{or } C). \]

P-values for the overlap between projected networks at Jaccard index cutoff of 0.9 and the Protein–Protein Interaction (PPI) network were calculated using hypergeometric test and adjusted using Benjamini-Hochberg method.

**Interaction networks and databases.** PPI network was curated by combining the databases BIND—Biomolecular Interaction Database, BioGRID—Biological Repository for Interaction Datasets, DIP—Database of Interacting Proteins, HIEPPI—Human Integrated Protein–Protein Interaction Reference, HPRD—Human Protein Reference Database, IntAct, MINT—Molecular INTeraction database, NetworKIN, PDZBase—PPI database for PDZ-domains, and Reactome. This resulted in 501,227 interactions between 18,023 proteins. The protein complexes data was downloaded from CORUM (The comprehensive resource of mammalian complexes) database which consists of 4274 complexes built from 4473 genes. Gene Ontology data was downloaded from the Gene Ontology Annotation (GOA) database. Gene group data was downloaded from HGNCC—HUGO (Human Genome Organisation—Gene Nomenclature Committee). For each cluster, gene group enrichment was tested using hypergeometric test and the corresponding P-values were adjusted using Benjamini–Hochberg method. Networks were visualized using Cytoscape v3.7.1. All data were analyzed using in-house python and shell scripts.

Received: 26 August 2020; Accepted: 30 September 2021
Published online: 02 November 2021

**References**

1. World Health Organization. *Global cancer data* (GLOBOCAN 2018 database at http://gco.iarc.fr/) (2018).
2. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. *Cell* **144**, 646–674 (2011).
3. Fry, D. C. & Vassilev, L. T. Targeting protein–protein interactions for cancer therapy. *J. Mol. Med. (Berl.)* **83**, 955–963 (2005).
4. Dreesen, O. & Brivanlou, A. H. Signaling pathways in cancer and embryonic stem cells. *Stem Cell Rev.** **3**, 7–17 (2007).
5. Alaimo, S., Marecchia, G. P., Ferro, A. & Pulvirenti, A. Detecting disease specific pathway substructures through an integrated systems biology approach. *Non-coding RNA** **3**, 20 (2017).
6. Network, C. G. A. R. et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* **45**, 1113–1120 (2013).
7. Segal, E., Friedman, N., Koller, D. & Regev, A. A module map showing conditional activity of expression modules in cancer. Nat. Genet. 36, 1090–1098 (2004).
8. Krupp, M. et al. The functional cancer map: A systems-level synopsis of genetic deregulation in cancer. BMC Med. Genom. 4, 53 (2011).
9. Xue, J.-M., Liu, Y., Wan, L.-H. & Zhu, Y.-X. Comprehensive analysis of differential gene expression to identify common gene signatures in multiple cancers. Med. Sci. Monit. 26, e919953–e919953 (2020).
10. Li, M., Sun, Q. & Wang, X. Transcriptional landscape of human cancers. Oncotarget 8, 34534–34551 (2017).
11. Zhao, J., Lee, S. H., Huss, M. & Holme, P. The network organization of cancer-associated protein complexes in human tissues. Sci. Rep. 3, 1583 (2013).
12. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C. & Aparicio, S. A. J. R. Europe PMC Funders Group Signatures of mutational processes in human cancer. Nature 500, 415–421 (2014).
13. Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134–1140 (2013).
14. Saqi, M., Lysenko, A., Guo, Y. K., Tsunoda, T. & Auffray, C. Navigating the disease landscape: Knowledge representations for contextualizing molecular signatures. Brief. Bioinform. 20, 609–623 (2019).
15. Fionda, V. Networks in biology. Encyl. Bioinf. Comput. Biol. 1, 915–921 (2019).
16. Asratian, A. S., Denley, T. M. J. & Häggkvist, R. Bipartite Graphs and Their Applications. Cambridge Tracts in Mathematics NV-131 (Cambridge University Press, 1998).
17. Watts, D. J. & Strogatz, S. H. Strogatz—Small world network. Nature 393, 440–442 (1998).
18. Newman, M. E. Scientific collaboration networks. I. Network construction and fundamental results. Phys. Rev. E. Stat. Nonlinear Soft Matter Phys. 64, 16131 (2001).
19. Goh, K. I. et al. The human disease network. Proc. Natl. Acad. Sci. U. S. A. 104, 8685–8690 (2007).
20. Zhou, T., Ren, L., Medo, M. & Zhang, Y.-C. Bipartite network projection and personal recommendation. Phys. Rev. E. Stat. Nonlinear Soft Matter Phys. 76, 46115 (2007).
21. Cheng, F., Zhao, J. & Zhao, Z. Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. Brief. Bioinform. 17, 642–656 (2016).
22. Song, J., Peng, W. & Wang, F. A random walk-based method to identify driver genes by integrating the subcellular localization and variation frequency into bipartite graph. BMC Bioinf. 20, 1–17 (2019).
23. Timilsina, M., Yang, H., Sahay, R. & Rehholz-Schuhmann, D. Predicting links between tumor samples and genes using 2-Layered graph based diffusion approach. BMC Bioinf. 20, 1–20 (2019).
24. Wang, Q. et al. Data descriptor: Unifying cancer and normal RNA sequencing data from different sources. Sci. Data 5, 1–8 (2018).
25. Catherino, W. H. et al. Reduced dermatopontin expression is a molecular link between uterine leiomyomas and keloids. Genes Chromosomes Cancer 40, 204–217 (2004).
26. Wang, H. I. et al. Decreased expression of PTH1R is a poor prognosis in hepatocellular carcinoma. Cancer Biomark. 21, 723–730 (2018).
27. Kuleshov, M. V. et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 44, W90–W97 (2016).
28. Ambrosini, G., Adda, C. & Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3, 917–921 (1997).
29. Mobahat, M., Narendran, A. & Riabowol, K. Survivin as a preferential target for cancer therapy. Int. J. Mol. Sci. 15, 2494–2516 (2014).
30. Hao, Z., Zhang, H. & Cowell, J. Ubiquitin-conjugating enzyme UBE2C: Molecular biology, role in tumorigenesis, and potential as a biomarker. Tumour Biol. 33, 723–730 (2012).
31. Kokuryo, T. et al. NEK2 is an effective target for cancer therapy with potential to induce regression of multiple human malignancies. Anticancer Res. 39, 2251–2258 (2019).
32. Faust, K. Centrality in affiliation networks. Soc. Netw. 19, 157–191 (1997).
33. Li, Y. R. & Yang, W. X. Myosins as fundamental components during tumorigenesis: Diverse and indispensable. Oncotarget 7, 46785–46812 (2016).
34. Watanabe, T. et al. Protein phosphatase 1 regulation by inhibitors and targeting subunits. Proc. Natl. Acad. Sci. U. S. A. 98, 3080–3085 (2001).
35. Bunnell, T. M., Burbach, B. J., Shimizu, Y. & Ervasti, J. M. β-Actin specifically controls cell growth, migration, and the G-actin pool. Mol. Biol. Cell 22, 4047–4058 (2011).
36. Senner, V. et al. AMOG/beta2 and glioma invasion: Does loss of AMOG make tumour cells run amok?. Neuropathol. Appl. Neurobiol. 29, 370–377 (2003).
37. He, B. et al. CTNNAS3 is a tumor suppressor in hepatocellular carcinomas and is inhibited by miR-425. Oncotarget 7, 8078–8098 (2016).
38. Zhou, X. et al. Myosin light-chain kinase contributes to the proliferation and migration of breast cancer cells through cross-talk with activated ERK1/2. Cancer Lett. 270, 312–327 (2008).
39. Kalla, R. S. & Bapat, S. A. Expression proteomics predicts loss of RXX-R during progression of epithelial ovarian cancer. PLoS One 8, e70398 (2013).
40. Hoadley, K. A. et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell 158, 929–944 (2014).
41. Aimopuro, P. et al. Somatic mutation analysis of MYH11 in breast and prostate cancer. BMC Cancer 8, 1–5 (2008).
42. Cui, J. et al. Epigenetic silencing of TPM2 contributes to colorectal cancer progression upon RhoA activation. Tumor Biol. 37, 12477–12483 (2016).
43. Song, L. et al. SORBS1 suppresses tumor metastasis and improves the sensitivity of cancer to chemotherapy drug. Oncotarget 8, 9108–9112 (2017).
44. Wang, H. et al. The mitotic regulator Hect1 is a critical modulator of prostate cancer through the long non-coding RNA BX647187 in vitro. Biosci. Rep. 35, 1–10 (2015).
45. Koleck, T. A. et al. An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors. Breast Cancer Targets Ther. 9, 95–110 (2017).
46. Kabisch, M. et al. Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis 36, 256–271 (2014).
47. Park, J., Wood, M. A. & Cole, M. D. BAFl3 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation. Mol. Cell. Biol. 22, 1307–1316 (2002).
48. Chatterjee, N. & Walker, G. C. Mechanisms of DNA damage, repair, and mutagenesis. Environ. Mol. Mutagen. 58, 235–263 (2017).
49. Purves, D., Augustine, G. J., Fitzpatrick, D. et al. editors. Neuroscience. 2nd ed. (Sinauer Associates, 2001). Taste Receptors a nd the Transduction of Taste Signals. (Accessed 22 December 2019); https://www.ncbi.nlm.nih.gov/books/NBK1148/.
50. Purves, D., Augustine, G. J., Fitzpatrick, D. et al. editors. Neuroscience. 2nd ed. (Sinauer Associates, 2001). The Transduction of Offactory Signals. (Accessed 22 December 2019); https://www.ncbi.nlm.nih.gov/books/NBK11039/.
51. Ween, J. L. & Potts, P. R. The MAGE protein family and cancer. Curr. Opin. Cell Biol. 37, 1–8 (2015).
52. Turraee, V., Marx, I. & Denis, C. V. Role of von Willebrand factor in tumor metastasis. Thromb. Res. 120, 64–70 (2007).
53. Xu, Q., Krause, M., Samoylenko, A. & Vainio, S. Wnt signaling in renal cell carcinoma. *Cancers (Basel)*. **8**, 57 (2016).
54. Coopers, A., Henry, C. E., Llamosas, E. & Ford, C. E. An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target. *Endocr. Relat. Cancer* **25**, R647–R662 (2018).
55. Consortium, Gt. The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).
56. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2009).
57. Han, H. et al. TRRUST: A reference database of human transcriptional regulatory interactions. *Sci. Rep.* **5**, 1–11 (2015).
58. Bovolenta, L. A., Accinio, M. L. & Lemke, N. HTTRIdb: An open-access database for experimentally verified human transcriptional regulation interactions. *BMC Genom.* **13**, 1–10 (2012).
59. Encode Consortium, Carolina, N. & Hill, C. For Junk DNA. *Nature* **489**, 57–74 (2013).
60. Liu, Z. P., Wu, C., Miao, H. & Wu, H. RegNetwork: An integrated database of transcriptional and post-transcriptional regulatory networks in human and mouse. *Database* **2015**, 1–12 (2015).
61. Latapy, M., Magnien, C. & Del Vecchio, N. Basic notions for the analysis of large two-mode networks. *Soc. Netw.* **30**, 31–48 (2008).
62. Bader, G. D., Betel, D. & Hogue, C. W. V. BIND: The biomolecular interaction network database. *Nucleic Acids Res.* **31**, 248–250 (2003).
63. Chatr-Aryamontri, A. et al. The BioGRID interaction database: 2015 update. *Nucleic Acids Res.* **43**, D470–D478 (2015).
64. Xenarios, I. et al. DIP: The databases of interacting protein: 2001 update. *Nucleic Acids Res.* **29**, 239–241 (2001).
65. Schaefer, M. H. et al. Hippie: Integrating protein interaction networks with experiment based quality scores. *PLoS One* **7**, 1–8 (2012).
66. Keshava Prasad, T. S. et al. Human protein reference database—2009 update. *Nucleic Acids Res.* **37**, 767–772 (2009).
67. Hermjakob, H. et al. IntAct: An open source molecular interaction database. *Nucleic Acids Res.* **32**, 452–455 (2004).
68. Chatr-aryamontri, A. et al. MINT: The Molecular INTeraction database. *Nucleic Acids Res.* **35**, 2006–2008 (2007).
69. Linding, R. et al. NetworkKin: A resource for exploring cellular phosphorylation networks. *Nucleic Acids Res.* **36**, 695–699 (2008).
70. Beuming, T., Skrabanek, L., Niv, M. Y., Mukherjee, P. & Weinstein, H. PDZBase: A protein–protein interaction database for PDZ-domain. *Bioinformatics* **21**, 827–828 (2005).
71. Croft, D. et al. Reactome: A database of reactions, pathways and biological processes. *Nucleic Acids Res.* **39**, 691–697 (2011).
72. Giugas, M. et al. CORUM: The comprehensive resource of mammalian protein complexes - 2019. *Nucleic Acids Res.* **47**, D559–D563 (2019).
73. Camon, E. et al. The Gene Ontology Annotation (GOA) Database: Sharing knowledge in uniprot with gene ontology. *Nucleic Acids Res.* **32**, 262–266 (2004).
74. Bruford, E. et al. The HGNC database in 2008: A resource for the human genome. *Nucleic Acids Res.* **36**, 445–448 (2008).
75. Shannon, P. et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Res.* **13**, 2498–2504 (2003).

**Acknowledgements**

We are thankful to Dr. Rangapriya Sundararajan and Dr. H Subramanya for the useful discussions.

**Author contributions**

Conceptualization, S.R.H.; methodology, D.L.V., D.P., H.G.S. and S.R.H.; data curation, D.L.V., D.P. and H.G.S.; formal analysis, D.L.V., D.P., H.G.S. and S.R.H.; investigation, S.R.H.; writing, D.L.V., D.P., H.G.S. and S.R.H. All authors have read and agreed to the final version of the manuscript.

**Funding**

This work was supported by the intra-mural funding of the Institute of Bioinformatics and Applied Biotechnology by the Department of IT, BT and S&T of the Government of Karnataka.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-00879-2.

**Correspondence** and requests for materials should be addressed to S.R.H.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021